Kawin Biopharma

Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Biopharma) is a leading Chinese biopharmaceutical company specializing in the research, development, and commercialization of therapies for viral diseases and liver disorders. The company is a dominant player in the domestic hepatitis market, anchored by its flagship product Pebitron (Pegylated Interferon alfa-2b), which is widely used for chronic hepatitis B and C. Kawin Biopharma maintains an integrated value chain that includes advanced R&D centers and large-scale GMP manufacturing facilities for both biologics and small molecules. Its strategic pipeline is focused on achieving functional cures for hepatitis B through innovative combination regimens involving monoclonal antibodies and capsid inhibitors. Publicly listed on the Shanghai Stock Exchange STAR Market, the company continues to expand its portfolio into immunology and other infectious disease areas.